Cover Image
市場調查報告書

椎管狹窄症的開發中產品分析

Spinal Stenosis - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 255977
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
椎管狹窄症的開發中產品分析 Spinal Stenosis - Pipeline Review, H1 2015
出版日期: 2015年02月10日 內容資訊: 英文 42 Pages
簡介

所謂椎管狹窄症,是指骨髓骨(脊樑骨)內部的空間變窄,脊椎和神經受壓迫的狀態。椎管狹窄症的主要症狀是,步行時頻繁跌倒、變得僵硬、感覺疼痛 、變得難以行走、刺痛、覺得腿部很熱/很冷等。主要的易罹病素質有年齡等。有代表性的治療方法,有非類固醇消炎劑(NSAID)和肌肉鬆弛劑、抗憂鬱劑、抗痙攣劑等。

本報告提供全球各國的椎管狹窄症治療用的開發中產品的開發情形相關分析、開發中產品的開發與上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介、主要藥物概要、最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

椎管狹窄症概要

治療藥的開發

  • 椎管狹窄症之開發中產品:概要
  • 椎管狹窄症之開發中產品:比較分析

各企業開發中的椎管狹窄症治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

椎管狹窄症治療藥:開發中產品一覽(各企業)

椎管狹窄症治療藥的開發企業

  • Mesoblast Limited
  • LTT Bio-Pharma Co., Ltd.
  • Sucampo Pharmaceuticals, Inc.

椎管狹窄症:治療藥的評估

  • 單劑治療藥的情況
  • 各標的
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • SPI-017
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ecraprost
  • NeoFuse
  • SPI-3608
  • LT-0101

椎管狹窄症治療藥:開發中產品的最新趨勢

椎管狹窄症相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿(1件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6317IDB

Summary

Global Markets Direct's, 'Spinal Stenosis - Pipeline Review, H1 2015', provides an overview of the Spinal Stenosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Spinal Stenosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Spinal Stenosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Spinal Stenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Spinal Stenosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Spinal Stenosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Spinal Stenosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Spinal Stenosis Overview
  • Therapeutics Development
    • Pipeline Products for Spinal Stenosis - Overview
    • Pipeline Products for Spinal Stenosis - Comparative Analysis
  • Spinal Stenosis - Therapeutics under Development by Companies
  • Spinal Stenosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Spinal Stenosis - Products under Development by Companies
  • Spinal Stenosis - Companies Involved in Therapeutics Development
    • LTT Bio-Pharma Co., Ltd.
    • Mesoblast Limited
    • Sucampo Pharmaceuticals, Inc.
    • Toray Industries, Inc.
    • Yungjin Pharm Ind. Co., Ltd.
  • Spinal Stenosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • beraprost sodium SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-0101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MPC-25Osteo - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-017 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-3608 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YLS-1501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Spinal Stenosis - Recent Pipeline Updates
  • Spinal Stenosis - Dormant Projects
  • Spinal Stenosis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 23, 2013: Sucampo Reports Results from Phase 2a Study of Intravenous Ion Channel Activator for Lumbar Spinal Stenosis
      • Jan 11, 2013: Mesoblast's Neofuse Stem Cell Product Shows Positive Results In Phase II Lumbar Spinal Fusion Trial
      • Jan 11, 2013: Mesoblast's Neofuse Stem Cell Product Shows Positive Results In Phase II Lumbar Spinal Fusion Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Spinal Stenosis, H1 2015
  • Number of Products under Development for Spinal Stenosis - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Spinal Stenosis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015
  • Spinal Stenosis - Pipeline by Mesoblast Limited, H1 2015
  • Spinal Stenosis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015
  • Spinal Stenosis - Pipeline by Toray Industries, Inc., H1 2015
  • Spinal Stenosis - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Spinal Stenosis Therapeutics - Recent Pipeline Updates, H1 2015
  • Spinal Stenosis - Dormant Projects, H1 2015

List of Figures

  • Number of Products under Development for Spinal Stenosis, H1 2015
  • Number of Products under Development for Spinal Stenosis - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top